問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

許雅婷Hsu, Ya-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

121Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許雅婷

List

167Cases

2019-09-01 - 2026-12-31

Phase II

Active
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    Pembrolizumab

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2023-11-01 - 2031-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.

  • Condition/Disease

    Essential Thrombocythemia

  • Test Drug

    MK-3543

Participate Sites
5Sites

Recruiting5Sites

2023-10-15 - 2033-12-31

Phase III

Active
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

  • Condition/Disease

    Chronic Lymphocytic Leukemia， Small Lymphocytic Lymphoma

  • Test Drug

    MK-1026MK-1026

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2024-11-20 - 2034-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-10-01 - 2031-09-01

Phase III

Active
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

  • Condition/Disease

    ER+/HER2- Breast Cancer

  • Test Drug

    Keytruda

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2022-12-01 - 2031-12-31

Phase III

Active
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

  • Condition/Disease

    Chronic Lymphocytic Leukemia、Small Lymphocytic Lymphoma

  • Test Drug

    1026FludarabineCyclophosphamideMK-1026

Participate Sites
3Sites

Recruiting3Sites

2021-10-01 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-12-25 - 2025-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-01-02 - 2029-06-01

Phase III

Active
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

  • Condition/Disease

    Adult Acute Myeloid Leukemia

  • Test Drug

    mocravimod

Participate Sites
4Sites

Recruiting4Sites

2019-08-09 - 2026-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

  • Condition/Disease

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

  • Test Drug

    Ponatinib

Participate Sites
4Sites

Recruiting3Sites

1 4 5 6 7 8 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB